ES2144426T3 - Terapia genica linfoquimica del cancer en combinacion con antigenos tumorales. - Google Patents

Terapia genica linfoquimica del cancer en combinacion con antigenos tumorales.

Info

Publication number
ES2144426T3
ES2144426T3 ES92922731T ES92922731T ES2144426T3 ES 2144426 T3 ES2144426 T3 ES 2144426T3 ES 92922731 T ES92922731 T ES 92922731T ES 92922731 T ES92922731 T ES 92922731T ES 2144426 T3 ES2144426 T3 ES 2144426T3
Authority
ES
Spain
Prior art keywords
tumor
gene
patient
lymphocemical
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92922731T
Other languages
English (en)
Inventor
Robert E Sobol
H Gage Fred
Ivor Royston
Theodore Friedman
Habib Fakhrai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sidney Kimmel Cancer Center
Original Assignee
Sidney Kimmel Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27119842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2144426(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sidney Kimmel Cancer Center filed Critical Sidney Kimmel Cancer Center
Application granted granted Critical
Publication of ES2144426T3 publication Critical patent/ES2144426T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DESCRIBE UN NUEVO METODO DE INMUNOTERAPIA DE TUMOR COMPRENDIENDO LA MODIFICACION GENETICA DE LAS CELULAS RESULTANTES EN LA SECRECION DE LOS PRODUCTOS DEL GEN CITOCINA PARA ESTIMULAR UNA RESPUESTA INMUNE DEL PACIENTE A LOS ANTIGENOS DEL TUMOR. EN UN CASO, LOS FIBROBLASTOS AUTOLOGOS GENETICAMENTE MODIFICADOS PARA SEGREGAR AL MENOS UN PRODUCTO DEL GEN CITOCINA SON UTILIZADOS PARA INMUNIZAR AL PACIENTE EN UNA FORMULA CON LOS ANTIGENOS DE TUMOR A UN SITIO DIFERENTE AL SITIO DEL TUMOR ACTIVO. EN OTRO CASO, LAS CELULAS GENETICAMENTE MODIFICADAS PARA EXPRESAR AL MENOS UN PRODUCTO DEL ANTIGENO DE TUMOR Y PARA SEGREGAR AL MENOS UN PRODUCTO DE GEN DE CITOCINA SON UTILIZADOS EN UNA FORMULA PARA INMUNIZAR AL PACIENTE EN UN LUGAR DISTINTO QUE UN LUGAR DE TUMOR ACTIVO.
ES92922731T 1991-10-25 1992-10-23 Terapia genica linfoquimica del cancer en combinacion con antigenos tumorales. Expired - Lifetime ES2144426T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78135691A 1991-10-25 1991-10-25
US86364192A 1992-04-03 1992-04-03

Publications (1)

Publication Number Publication Date
ES2144426T3 true ES2144426T3 (es) 2000-06-16

Family

ID=27119842

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92922731T Expired - Lifetime ES2144426T3 (es) 1991-10-25 1992-10-23 Terapia genica linfoquimica del cancer en combinacion con antigenos tumorales.

Country Status (9)

Country Link
EP (1) EP0668781B1 (es)
JP (1) JP3524918B2 (es)
AT (1) ATE188125T1 (es)
CA (1) CA2121127A1 (es)
DE (1) DE69230506T2 (es)
DK (1) DK0668781T3 (es)
ES (1) ES2144426T3 (es)
GR (1) GR3032660T3 (es)
WO (1) WO1993007906A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US6133029A (en) * 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US6569679B1 (en) 1988-03-21 2003-05-27 Chiron Corporation Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US5997859A (en) * 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
FR2710536B1 (fr) * 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
WO1995014091A2 (en) 1993-11-18 1995-05-26 Chiron Viagene, Inc. Compositions and methods for utilizing conditionally lethal genes
FR2713657B1 (fr) * 1993-12-13 1996-03-01 Transgene Sa Nouveaux vecteurs pour le traitement du sida.
EP0734440A1 (en) * 1993-12-14 1996-10-02 Yajun Guo Tumor cell fusions and methods for use of such tumor cell fusions
DE4406073A1 (de) * 1994-02-24 1995-08-31 Univ Ludwigs Albert Verfahren zur Herstellung von humanen, klonogenen Fibroblasten, Verfahren zur Gentransfizierung von Fibroblasten und so erhaltene Fibroblasten
US5759535A (en) * 1994-05-13 1998-06-02 Research Corporation Technologies, Inc. Immunotherapeutic strategies for the treatment of cancer
US5772995A (en) * 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
JP3822261B2 (ja) * 1994-09-09 2006-09-13 財団法人癌研究会 癌の遺伝子治療剤
WO1996013275A1 (en) * 1994-10-31 1996-05-09 Tkb Associates Limited Partnership Methods and products for enhancing immune responses
EP0817858B1 (en) * 1995-03-09 2003-04-23 Austrian Nordic Biotherapeutics AG Vectors carrying therapeutic genes encoding antimicrobial peptides for gene therapy
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
EP0834323A1 (en) * 1996-09-30 1998-04-08 Introgene B.V. Cytokine gene therapy for treatment of malignacies
EP1012240B1 (en) 1997-01-31 2008-03-19 Edward P. Cohen Cancer immunotherapy with semi-allogeneic cells
JP4303887B2 (ja) * 1998-02-02 2009-07-29 ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン 普遍的免疫調節サイトカイン発現バイスタンダー細胞系、その関連組成物、その製造方法およびその使用
US6342216B1 (en) * 1999-03-17 2002-01-29 The Board Of Regents, The University Of Texas System Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
US7101543B2 (en) 2000-03-31 2006-09-05 Novarx Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
EP2314322A1 (en) * 2000-03-31 2011-04-27 Novarx Compositions containing genetically modified lung cancer cells expressing a TGF-beta inhibitor
EP1285059A2 (en) 2000-05-31 2003-02-26 The Board Of Regents, The University Of Texas System Adjuvant preparation for the induction of specific immunity
AU2005205441A1 (en) * 2004-01-13 2005-07-28 Dnavec Research Inc. Gene therapy for tumor using minus-strand RNA virus vector encoding immunostimulating cytokine
US20090214494A1 (en) 2005-03-29 2009-08-27 The Board Of Trustees Of The University Of Illinoi Cancer Vaccines and Therapeutic Methods
WO2021087439A1 (en) * 2019-11-02 2021-05-06 Figene, Llc Intratumoral administration of immune cellular therapeutics

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2080341T3 (es) * 1990-09-14 1996-02-01 Univ Johns Hopkins Metodos y composiciones para la terapia genetica y la potenciacion de la inmunidad antitumoral.

Also Published As

Publication number Publication date
DE69230506D1 (de) 2000-02-03
ATE188125T1 (de) 2000-01-15
DE69230506T2 (de) 2000-06-21
GR3032660T3 (en) 2000-06-30
JPH07503455A (ja) 1995-04-13
CA2121127A1 (en) 1993-04-29
EP0668781B1 (en) 1999-12-29
WO1993007906A1 (en) 1993-04-29
JP3524918B2 (ja) 2004-05-10
DK0668781T3 (da) 2000-04-17
EP0668781A1 (en) 1995-08-30
EP0668781A4 (en) 1995-06-14

Similar Documents

Publication Publication Date Title
ES2144426T3 (es) Terapia genica linfoquimica del cancer en combinacion con antigenos tumorales.
Abbott et al. Cancer and the immune system: the history and background of immunotherapy
Chen et al. Tumor cell membrane-bound heat shock protein 70 elicits antitumor immunity
FI924069A (fi) Terapeutiskt anvaendbara peptider och peptidfragment
ZA91559B (en) Vaccines against cancer and infectious diseases
ES2112860T3 (es) Inmunoterapia adoptiva con interleukina-7.
EP0857068A4 (en) IMMUNOTHERAPY OF CANCER AND INFECTIOUS DISEASES USING SENSITIZED ANTIGEN PRESENT CELLS WITH THERMAL SHOCK-ANTIGEN PROTEIN COMPLEXES
HK1086750A1 (en) Pharmaceutical composition for inducing an immune response in a human or animal
NO991691L (no) Cancer immunoterapi ved Õ bruke tumorceller kombinert med blandede lymfosytter
Schultz et al. Long-lasting anti-metastatic efficiency of interleukin 12-encoding plasmid DNA
DK0702563T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme
DE69839273D1 (de) Krebs immuntherapie mit semi-allogenen zellen
Agrawal et al. Current studies of immunotherapy on glioblastoma
León-Letelier et al. Induction of progenitor exhausted tissue-resident memory CD8+ T cells upon salmonella typhi porins adjuvant immunization correlates with melanoma control and anti-PD-1 immunotherapy cooperation
Santin et al. Effects of irradiation on the expression of surface antigens in human ovarian cancer
HUP0204216A2 (en) A new use of antibodies as vaccines
NZ507829A (en) Vaccine adjuvants for immunotherapy of melanoma
ES2137172T3 (es) Vacunas antitumorales que comprenden celulas transfectadas con il-6.
Barr et al. Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer
CN1887296B (zh) 一种诱导抗肿瘤免疫的方法及其在制药中的应用
IL92009A0 (en) Cell lines,monoclonal anti-bodies and pharmaceutical compositions containing the same
DE69433110D1 (de) Allogenes vakzin und synthesemethode für selbiges
Flamand et al. Vaccination with Tumor Antigen-Pulsed Dendritic Cells Induces in Vivo Resistance to AB Cell Lymphoma
ATE385809T1 (de) Saponin-zusammensetzungen und deren verwendung
Jang et al. Simultaneous expression of allogenic class II MHC and B7. 1 (CD80) molecules in A20 B-lymphoma cell line enhances tumor immunogenicity

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 668781

Country of ref document: ES